Portola Pharma (PTLA) Misses Q1 EPS by 5c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($0.74), $0.05 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $20.46 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• UBS Upgrades Geely Automotive Holdings Ltd. (175:HK) (GELYF) to Buy
• UBS Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Neutral